Home Category Region Publishers About Us Contact Us
Japanese Korean Chinese
Home > Market Research Report > Pharmaceutical > Regulation > China Pharmaceutical Regulatory Report 2010
Category
Pharmaceutical (4993)
Bone Disease Treatment (46)
Cancer (884)
Diabetes (159)
Drug Delivery System (184)
Drug Discovery (1403)
Generic Drugs (128)
Infectious Disease (407)
Mental Disease (98)
Neurodegenerative Disease (180)
Obesity Treatment (49)
OTC Drug (149)
Pharmaceutical Companies (562)
Prescription Drugs (120)
Regulation (122)
Vaccines (178)
Veterinary Medicine (28)
Market Research Report

China Pharmaceutical Regulatory Report 2010

Published by Pacific Bridge Medical
Published January, 2010 Product code 108199
Content info 70 pages
Price
US $ 750 Hard Copy without appendix
US $ 1500 Hard Copy with appendix


China Pharmaceutical Regulatory Report 2010 published by Pacific Bridge Medical in January, 2010. This report consists of 70 pages and the price starts from US $ 750.

Introduction

Abstract

Overview:

This report includes a brief overview of the pharmaceutical and healthcare industry in China, as well as a discussion of all the relevant laws and regulations that govern the testing, registration, manufacture, import, marketing, and sale of pharmaceutical products. Specific topics include: product registration, pricing and reimbursement, importation, GMP, GCP, orphan drugs, and intellectual property protection.

This report' s appendix contains a full translation of the revised Administrative Provisions for Drug Registration, the recent overhaul of China' s drug regulations. It also contains the annexes to this document detailing dossier submission requirements, all up-to-date.

You can purchase this 70-page report for $750. For $1500, you can purchase the report plus the 125-page appendix including translations of key pharmaceutical regulations, pharmaceutical statistics, registration forms, China CRO contacts, and a timeline for the pharmaceutical registration process.

Fully updated for 2010!

Completely new information has been added to this report, including distribution in Section I, the 2009 Health Care Reform in Section II, new regulatory changes in Section III, drug purchasing system in Section VII, and drug safety in Section VIII. There are also updates on drug registration statistics, GMP, re-registration processes, and packing requirements. The appendix has also been updated, such as CRO information and SFDA affiliate organizations.

Table of Contents

I. China Pharmaceutical Industry Overview

  • A. Overview
  • B. China Pharmaceutical Market Trends
  • C. China' s Pharmaceutical Distribution System
  • D. Brief Overview of China' s Pharmaceutical Regulations
  • E. The State Food and Drug Administration

II. The China Healthcare System

  • A. History of Healthcare System in China
  • B. Struggling Healthcare Services Sector
  • C. Hospitals and Medical Resources
  • D. Health Insurance in China
  • E. 2009 Health Care Reform

III. Drug Registration Regulations

  • A. Drug Registration Policy
  • B. Classification of Drugs
  • C. Drug Registration Application
  • D. Application Documents for New Drug Registration
  • E. Technical Review Guidance for Registration Documents
  • F. New Drug Registration Process
  • G. OTC New Drug Registration Process
  • H. New Drug Registration Statistics
  • I. Classification of Combination Drug-Device Products
  • J. New Regulatory Changes

IV. Drug Pricing Regulations

  • A. Overview of Drug Pricing
  • B. Controls on Drug Pricing
  • C. National Essential Medical Insurance Drug List

V. Pharmaceutical Research and Development and Related Regulations

  • A. China' s Research and Development Climate
  • B. Clinical Research
  • C. Good Clinical Practice (GCP)
  • D. GCP-Certified Clinical Research Centers
  • E. Good Laboratory Practice (GLP)
  • F. Adverse Event Reporting Requirements

VI. Pharmaceutical Manufacturing Regulations

  • A. Manufacturing Pharmaceuticals in China
  • B. GMP Regulations
  • C. GMP Certification
  • D. Drug Manufacturing Administration
  • E. Drug Manufacturing Certificate
  • F. Biological Products

VII. Selling Pharmaceuticals and Related Regulations

  • A. WTO Agreement on Drug Sales
  • B. Drug Sales to Hospitals
  • C. Drug Purchasing System
  • D. Selling Drugs in Drug Stores
  • E. Drug Sales on the Internet
  • F. Distribution Regulations
  • G. OTC Drug Sales
  • H. Regulations on Drug Imports
  • I. Drug Recalls

VIII. Drug Safety

IX. Authorized Quality Person

X. Marketing Drugs in China

  • A. Packaging Requirements

XI. Drug Advertising

XII. Intellectual Property Protection

  • A. Current Intellectual Property Situation in China Pharmaceutical Market
  • B. Examples of Pharmaceutical Companies Experience with IPR infringement in China
  • C. Administration Protection (AP)

XIII. Conclusion

APPENDICES:

  • A. Application Form for Drug Registration
  • B. Listing of CROs in China; Regulatory Specifics for Clinical Trials in China
  • C. Administrative Provisions for Drug Registration (translated law)
  • D. Registration for TCM (translated law)
  • E. Registration for Chemical Drugs (translated law)
  • F. Registration for Biological Drugs (translated law)
  • G. Supplemental Drug Application Registration (translated law)
  • H. Drug Re-registration Application (translated law)
  • I. Drug Monitoring Periods
  • J. Application and Approval Procedures and Timeline for Imported Drugs
  • K. Application and Approval Procedures and Timeline for Clinical Trials
  • L. Listing of SFDA-affiliated organizations in China
  • M. Healthcare statistics in Asia (charts)
Back to Top